Helicobacter pylori infection, insulin resistance and nonalcoholic fatty liver disease

Medical Hypotheses

Volumn 82, Issue 6, 2014, Pages 795-

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Zavos, Christos ^a   Deretzi, Georgia ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; IMMUNOGLOBULIN G; RECOMBINANT RNA; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT;

ANTIBODY TITER; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; ERADICATION THERAPY; HELICOBACTER INFECTION; HOMEOSTATIC MODEL OF ASSESSMENT INSULIN RESISTANCE; HUMAN; INSULIN RESISTANCE; LETTER; NONALCOHOLIC FATTY LIVER; DRUG EFFECTS; FATTY LIVER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MALE; METABOLOME; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; FATTY LIVER; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INSULIN RESISTANCE; MALE; METABOLOME;

EID: 84899649488     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2014.03.003     Document Type: Letter

References (5)

1. Abenavoli L., Milic N., Masarone M., Persico M. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. Med Hypotheses 2013, 81(5):913-915.
2. Polyzos S.A., Kountouras J., Zavos C., Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter 2011, 16(2):79-88.
3. Polyzos S.A., Kountouras J., Papatheodorou A., et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013, 62(1):121-126.
4. Pirouz T., Zounubi L., Keivani H., Rakhshani N., Hormazdi M. Detection of Helicobacter pylori in paraffin-embedded specimens from patients with chronic liver diseases, using the amplification method. Dig Dis Sci 2009, 54(7):1456-1459.
5. Dogan Z., Filik L., Ergul B., Sarikaya M., Akbal E. Association between Helicobacter pylori and liver-to-spleen ratio: a randomized-controlled single-blind study. Eur J Gastroenterol Hepatol 2013, 25(1):107-110.